



Published in final edited form as:

Curr Opin Neurobiol. 2013 August ; 23(4): 649–654. doi:10.1016/j.conb.2013.05.001.

The Clinical Neurobiology of Drug Craving

Rajita Sinha, PhD^{1,2,3}

¹Department of Psychiatry Yale University School of Medicine, Yale Stress Center, 2 Church Street South, Suite 209, New Haven, CT 06519

²Child Study Center, Yale University School of Medicine, New Haven, CT 06520

³Department of Neurobiology, Yale University School of Medicine, New Haven, CT 06520

Abstract

Drug craving has re-emerged as a relevant and important construct in the pathophysiology of addiction with its inclusion in DSM-V as a key clinical symptom of addictive disorders. This renewed focus has been due in part to the recent neurobiological evidence on craving-related neural activation and clinical evidence supporting its association with drug use, relapse and recovery processes. This review covers the neurobiology of drug craving and relapse risk with a primary focus on cocaine addiction and a secondary emphasis on alcohol addiction. A conceptualization of drug craving on the continuum of healthy desire and compulsive seeking, and the associated neurobiological adaptations associated with the development of an increased craving/wanting state is presented. Altered dopamine neurochemistry as well as disrupted prefrontal control and hyperactive striatal-limbic responses in experiencing drug cues, stress, drug intake and in basal relaxed states are identified as neurobiological signatures that predict drug craving and drug use. Thus, the clinical and neurobiological features of the craving/wanting state are presented with specific attention to alterations in these cortico-limbic-striatal and prefrontal self-control circuits that predict drug craving and relapse risk. The methodological challenges that need to be addressed to further develop the evolving conceptual approach in the neuroscience of drug craving is presented, with a focus on identification and validation of biomarkers associated with the craving state and treatment approaches that may be of benefit in reversing the neurobiological adaptations associated with drug craving to improve treatment outcomes in addiction.

Introduction

The concept of drug craving has had a long and chequered history in the science of addiction. While clinical reports of drug craving among addicted individuals have kept the construct alive and relevant, difficulties in developing reliable ways to provoke craving and assess its relevance to drug use, relapse and treatment outcome led to questions regarding its utility [1]; [2]. However, a number of scientific developments have led to a renewed emphasis on its relevance to addiction, resulting in the re-emergence of its importance as a

© 2013 Elsevier Ltd. All rights reserved.

Corresponding author: Rajita Sinha, Ph.D., Yale Stress Center, 2 Church Street South, Suite 209, New Haven, CT 06519, Tel: 203-737-5015, Fax: 203-737-1272.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Financial Disclosures: Dr. Sinha is on the Scientific Advisory Board for Embera Neurotherapeutics.

significant clinical symptom in the pathophysiology of addiction. First, the basic science incentive sensitization model of wanting/craving for drug [3]) and research modeling drug seeking in drug experiences or dependent animals [4]; [5]. Second, clinical research using reliable provocateurs of craving in the laboratory [6]; [7]; [8]; [9], ecological momentary assessment (EMA) approaches to studying craving and drug use episodes in real time in the daily lives of addicted individuals [10]; [11]; [12]) and treatment studies on drug craving predicting treatment outcome and relapse [13]; [14]; [15]; [16], although some negative studies have also been reported. Finally, there are a growing number of neuroimaging studies of the drug craving state and its relevance in drug use and relapse risk [17]; [18]; [19]; [20]; [21]; [22]; [23]. This paper briefly reviews this clinical neurobiological research and presents a renewed conceptualization of drug craving, its clinical relevance and neurobiology, and the challenges that need to be addressed in future research, to both establish the role of drug craving in the pathophysiology of addiction, and to assess its clinical utility as a target of treatment development to improve addiction treatment outcomes.

Development of Craving and Compulsive Seeking: Relevance to Drug Use and Relapse

Engaging in rewarding and pleasurable behaviors is a natural part of human existence. Exposure and access to hedonic stimuli like addicted drugs results in the pleasurable, positively reinforcing effects of the drug and also “desire” for that which is pleasurable when drug is not present. Indeed, drug-related stimuli and contexts (e.g., drug paraphernalia, passing a favorite bar, buying alcohol) may increase subjective desire for reward. Thus, light to moderate amounts of drug use elicit the rewarding effects of drug, which may increase desire for drug. Clearly small to moderate amounts of drug can be consumed with no signs of addiction, and indeed the majority of individuals using drugs like cocaine or alcohol do not develop addictive disorders. However, chronic and excessive levels of drug intake are associated with increased salience, as proposed by Robinson and Berridge [3], and a more intense, urgent “abnormal desire” characterized by longing, yearning and physiological need for drug which may be defined as “craving”[24].

While the mesolimbic dopaminergic and glutamatergic adaptations associated with high levels of drug intake are linked to a “wanting” or craving state [3]; [25], additional neurobiological adaptations in brain catecholaminergic, CRF and opioid systems have been reported, along with their contribution to the greater longing and physiological need for drug identified here as craving and compulsive seeking [26]; [27]. In human studies, heavy, non-dependent drinkers report higher levels of cue-induced drug craving than light drinkers. Increasing levels of anxiety and arousal are reported with increasing levels of drug craving as blood levels of cocaine decrease in addicted individuals [28]. In addition to anxiety, additional physiological and stress-like symptoms are associated with the drug craving state. For example, the cocaine craving state (distinct from mild, low level increase in subjective desire) is associated with irritability, restlessness, increases in heart rate, butterflies in stomach, nausea and other arousal symptoms that overlap with stress-related arousal [29]. Interestingly, we’ve consistently reported increases in drug craving with personalized stress exposure in different groups of treatment engaged abstinent addicts, that is minimally reported in healthy light social drinkers [9], and stress-induced increases in drug craving as well as drug-cue-induced increases in craving in the laboratory are predictive of future drug relapse risk [30]; [31] (unpublished data with drug cue-induced cocaine craving predictive of future cocaine relapse risk).

Ecological momentary assessment (EMA) approaches have shown acute increases in drug craving in daily life are directly predictive of subsequent episodes of drug use [12]; [10];

[11]; [32]. The research presented in the previous section suggests that phenomenologically, drug craving is a more reliable and measurable state in drug abusing individuals, in which the drug craving state increases with decreasing drug levels during drug taking (clinically characterized in cocaine-taking as “chasing the high”), but also with stress and drug cue exposure. This state is described by patients as mildly aversive, with increases in stress-related arousal, and significant associations between increased anxiety and high craving levels have been reported [9]. However, thus far, clinical studies show that increases in anxiety or distress does not predict drug intake or relapse, but concomitant increases in drug craving predicts subsequent drug taking and relapse [12]; [30]; [31]. Based on these data, it may be speculated that anxiety and distress, while increasing during craving, is not driving drug use in the context of stress, drug cues or falling blood levels of drug, but rather the stronger the craving, the more likely the individual will engage in drug intake. As proposed by Tiffany [1], conscious conflict about engaging in drug use or not would increase craving, and perhaps the strength of the craving modulation may predict relapse. Thus, although craving occurs in the context of high arousal states and is similar to conditions of stress, and anxiety and craving co-occur, it is craving through incentive motivation that predicts drug use, and not the concomitant increases in anxiety, as proposed in models of negative reinforcement and anxiety-related avoidance motivation [c.f. 3], and as elegantly shown in an animal study modeling incentive motivation under heroin withdrawal conditions [33]. This idea needs further empirical validation in human studies, but if supported, it would appear that with high levels of drug use, there is a progression from healthy desire to a stress-related arousal state characterized by physiological need and longing (craving), that via approach/incentive learning and habit-based processes may set in motion sensitized instrumental behaviors or habit-based responding away from goal directed responses [34]. Interestingly, such shifts from goal-directed responses to habit-based responding has also been well documented under stress, with stress inducing increases in habitual behaviors [35]. If these ideas are empirically validated, they may elude to a common pathway of high drug exposure-related adaptations in craving-related motivation that are common for conditions of stress, drug cues or drug.

Neurobiological Adaptations underlying the Drug Craving State

The shift from normal healthy desire to drug craving with increased levels of drug use is also associated with changes in limbic, striatal and cortical brain systems. For example, changes in hypothalamic pituitary adrenal (HPA) axis responses, altered and blunted amygdala response to fear/threat potentiated startle in heavy drinkers compared to light social drinkers and autonomic imbalances in sympathetic/parasympathetic systems have been reported with increased drug use [36]; [9]; [31]. With the rise of neuroimaging techniques, a number of studies have assessed neural changes associated with the drug craving state with correlations to subjective drug craving and to drug use/relapse. Brief exposure to cocaine cues, known to increase drug craving, in cocaine dependent (CD) individuals increased activity in the amygdala and regions of the frontal cortex [37]; [17]; [18], and with gender differences reported in amygdala activity and the frontal cortex response in cocaine dependent individuals [38]; [39]. Cue induced craving for nicotine, methamphetamine and opiates also activate regions of the prefrontal cortex, amygdala, hippocampus, insula and the VTA (see [40]).

As stress also increases drug craving in addicted individuals relative to controls, brain activation during stress and neutral imagery in a functional magnetic resonance imaging (fMRI) study were assessed in healthy controls and CD individuals. While both groups showed similar levels of distress and pulse changes during stress exposure, brain response to emotional stress in paralimbic regions such as the anterior cingulate cortex (ACC), hippocampus and parahippocampal regions was greater in healthy controls during stress

while CD patients showed a striking absence of such activation [21]. In contrast, patients had increased activity in the caudate and dorsal striatum region during stress, activation that was significantly associated with stress-induced cocaine craving ratings. A larger follow-up study assessed brain response to stress, drug cues and neutral-relaxing cues using individualized guided imagery in CD versus healthy social drinking men and women [41]. Findings indicated that CD versus healthy women showed greater activation in limbic-striatal regions such as the amygdala, caudate-putamen, insula and ACC during stress, while CD men relative to male controls showed significantly greater responsiveness in these regions to drug cues and in the neutral relaxing condition. These data are consistent with previously cited evidence of increased reactivity to stress and drug cues during drug craving states in patients relative to controls, and also highlight the importance of examining sex differences in drug craving-related neuroadaptations.

Evidence from PET imaging research has further pointed to the brain neurochemistry involved in drug craving states. Significant positive correlations between D2 receptor binding in the dorsal striatum and drug cue-induced cocaine craving has been reported [42]; [43]). These findings are consistent with imaging studies in alcoholic patients who show increased association between dorsal striatum, dopamine and alcohol craving in response to presentation of alcohol related stimuli [44];[45]. In both CD patients and alcoholics, a significant association between dopamine D2 receptor binding in the VS and drug craving as well as motivation for self administration has been demonstrated [22]; [19]; [20].

As previous work has clearly shown that stress-induced and drug cue-induced craving is significantly greater in addicted individuals relative to controls [9], we also assessed brain correlates of stress and cue-induced alcohol craving in abstinent, treatment engaged alcohol dependent (AD) individuals. Findings indicate a robust hyperactivity during the neutral relaxed state in the ventral striatum and the ventromedial PFC (VmpFC)/ACC which correlated with provoked stress-induced and cue-induced drug craving [23]. Stress and drug cue-induced craving was also associated with blunted responses in these regions in the stress and drug cue conditions, and both hyperactivation of the VmpFC in the neutral relaxed state and hypoactivation of the VmpFC and the insula during stress was predictive of future time to alcohol relapse and severity of alcohol relapse during the subsequent recovery period [23]. These findings identify neuroadaptations in the VmpFC, ventral striatum and insula networks that show disrupted functioning in the relaxed state, and in turn, contributes to hypoactive responses during provoked/challenge conditions in addicted individuals.

Hypofrontal activation in the ACC and VmpFC during drug cue and stress-induced craving states as reported above is consistent with a growing literature from neuropsychological and imaging studies examining prefrontal executive functions, including impulse control, decision making and set shifting, which has shown executive function deficits and hypofrontal responses in addicted individuals compared to control volunteers [46]; [47]; [48]; [49]; [50]; [51]; [52]; [53]. Interestingly, evidence from research on stress-related shifts in goal direct motivation to habit-based responding also points to blunted responses in the medial PFC region [54]. Together, the neuroadaptations associated with addiction as well as the neural responses under conditions of stress suggest that disruption of VmpFC and ACC function with blunted responses in these regions during stress, drug cue and other challenge states may mediate increased drug craving and loss of behavioral control over drug craving. Whether it is blunted VmpFC/ACC responses due to stress/chronic drug exposure or stress-motivated habit responses or both that are required for increased risk of relapse are not fully understood. Certainly the human data from the alcohol relapse findings described above point to disrupted top-down control of cravings that increase relapse risk. A schematic representing drug craving on a dimensional continuum that is based on level of exposure and

drug history and associated neuroadaptations in circuitry and in neurochemistry (see previous reviews [55]; [31]) is presented in Figure 1.

Conclusion and Futures Directions

This review presents evidence to support drug craving as a dimensional construct that grows with increasing levels of drug use. With increased salience of drug, there is greater motivation or ‘wanting’ of drug as posited by the incentive sensitization model of addiction. Evidence from human experimental and neuroimaging studies also shows increases in stress-induced wanting along with higher drug cue-induced craving in the addicted state which is accompanied by increased levels of stress-related arousal, anxiety and expanded network of corticolimbic-striatal activation under stress, drug, drug cue and relaxed exposure conditions. Interestingly, several studies show disruption of medial prefrontal activity during both craving or cognitive challenge that is associated with drug use/relapse in addicted individuals. As the medial prefrontal region has been identified as an important region in self control, it appears that compromised self control may be a key aspect of the neurobiology of drug craving state.

Despite the growing evidence on the clinical neurobiology of drug craving, a number of methodological issues remain in studying craving and its provocation, particularly to understand mechanisms driving drug use and relapse risk. If drug craving builds with high levels of drug use and with increasing incentive salience as discussed above, there is a need to identify the behavioral, neurobiological and physiological adaptations that occur with increased levels of drug use even in the absence of addictive disorders, and specifically, the key components that predict development of craving and enhanced motivation for drug. Furthermore, identification of the neuro-biological components specific to the drug craving state may result in development of valid craving-related neural markers that may be targeted for future prevention and treatment efforts. For example, as data are accruing on disrupted prefrontal control over urges as a key component of the drug craving state, targeting such compromised prefrontal function as a biomarker for normalization with agents that rescue the prefrontal cortical neurons may represent a useful strategy in treatment development. Alternatively, strategies that reduce activity in the limbic-striatal network in response to drug, cues or stress may also be useful in reducing drug craving, drug use and relapse. Studies on increasing understanding of the neurobiology of aversive states that promote sensitization and approach behaviors as well as those on the neurobiology of inhibitory control processes and compulsive habits may contribute to improving strategies for reducing drug craving and relapse prevention in addiction. Finally, it is not known if the human brain recovers from addiction-related neuroadaptations and can return to healthy levels of desire. It may well be that a realistic goal is not to decrease limbic-striatal reactivity and related alterations associated with craving, but to improve self control and regulation of drug craving, which, with long term recovery may diminish craving circuits that drive habit, automaticity and relapse risk.

Acknowledgments

This work was supported by the NIH grants P50-DA16556-10, R01-DA027130, R01-AA013892 and the NIH Roadmap for Medical Research Common Fund Grants UL1-DE019586, UL1-RR024139 (Yale CTSA), and the PL1-DA024859.

References

*denotes special interest; ** outstanding interest

1. Carter BL, Tiffany ST. The cue-availability paradigm: the effects of cigarette availability on cue reactivity in smokers. *Exp Clin Psychopharmacol*. 2001; 9:183–190. [PubMed: 11518094]
- *2. O'Brien CP. Addiction and dependence in DSM-V. *Addiction*. 2010; 106:866–867. This brief perspective paper focuses on the changes included in the Substance Use Disorders section of the Diagnostic and Statistical Manual of Mental Disorders - version V, and includes the concept of physiological adaptations in the central nervous system and the rationale for addition of the "craving" criteria.
3. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. *Brain research. Brain research reviews*. 1993; 18:247–291. [PubMed: 8401595]
4. Shaham Y, Hope BT. The role of neuroadaptations in relapse to drug seeking. *Nature neuroscience*. 2005; 8:1437–1439.
5. Belin D, Balado E, Piazza PV, Deroche-Gamonet V. Pattern of intake and drug craving predict the development of cocaine addiction-like behavior in rats. *Biological psychiatry*. 2009; 65:863–868. [PubMed: 18639867]
6. Sinha R, Catapano D, O'Malley S. Stress-induced craving and stress response in cocaine dependent individuals. *Psychopharmacology*. 1999; 142:343–351. [PubMed: 10229058]
7. Sinha R, Fuse T, Aubin LR, O'Malley SS. Psychological stress, drug-related cues and cocaine craving. *Psychopharmacology*. 2000; 152:140–148. [PubMed: 11057517]
8. Sinha R, Talih M, Malison R, Cooney N, Anderson GM, Kreek MJ. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. *Psychopharmacology*. 2003; 170:62–72. [PubMed: 12845411]
9. Sinha R. Modeling stress and drug craving in the laboratory: implications for addiction treatment development. *Addiction biology*. 2009; 14:84–98. [PubMed: 18945295]
10. Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. *Journal of consulting and clinical psychology*. 1996; 64:366–379. [PubMed: 8871421]
11. Epstein DH, Willner-Reid J, Vahabzadeh M, Mezghanni M, Lin JL, Preston KL. Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. *Archives of general psychiatry*. 2009; 66:88–94. [PubMed: 19124692]
- *12. Preston KL, Epstein DH. Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use. *Psychopharmacology*. 2011; 218:29–37. [PubMed: 21336579] This recent study builds on work by these authors using the ecological momentary assessment approach in a prospective longitudinal cohort design to demonstrate that cocaine craving is tightly coupled to cocaine use in the users' normal environment and daily life and also addresses stress and negative mood relationships.
13. Paliwal P, Hyman SM, Sinha R. Craving predicts time to cocaine relapse: further validation of the Now and Brief versions of the cocaine craving questionnaire. *Drug and alcohol dependence*. 2008; 93:252–259. [PubMed: 18063320]
14. Rohsenow DJ, Martin RA, Eaton CA, Monti PM. Cocaine craving as a predictor of treatment attrition and outcomes after residential treatment for cocaine dependence. *Journal of studies on alcohol and drugs*. 2007; 68:641–648. [PubMed: 17690796]
15. Weiss RD, Griffin ML, Mazurick C, Berkman B, Gastfriend DR, Frank A, Barber JP, Blaine J, Salloum I, Moras K. The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use. *The American journal of psychiatry*. 2003; 160:1320–1325. [PubMed: 12832248]
16. Addolorato G, Abenavoli L, Leggio L, Gasbarrini G. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. *Neuropsychobiology*. 2005; 51:59–66. [PubMed: 15741745]
17. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced cocaine craving. *The American journal of psychiatry*. 1999; 156:11–18. [PubMed: 9892292]
18. Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, Ely TD, Hoffman JM, Drexler KP. Neural activity related to drug craving in cocaine addiction. *Archives of general psychiatry*. 2001; 58:334–341. [PubMed: 11296093]

19. Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A, Kegeles L, Talbot P, Evans S, Krystal J, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. *Biol Psychiatry*. 2005; 58:779–786. [PubMed: 16018986]
20. Martinez D, Kim JH, Krystal J, Abi-Dargham A. Imaging the neurochemistry of alcohol and substance abuse. *Neuroimaging Clin N Am*. 2007; 17:539–555. x. [PubMed: 17983969]
21. Sinha R, Lacadie C, Skudlarski P, Fulbright RK, Rounsaville BJ, Kosten TR, Wexler BE. Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study. *Psychopharmacology (Berl)*. 2005; 183:171–180. [PubMed: 16163517]
22. Heinz A, Siessmeier T, Wrase J, Buchholz HG, Grunder G, Kumakura Y, Cumming P, Schreckenberger M, Smolka MN, Rosch F, et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. *The American journal of psychiatry*. 2005; 162:1515–1520. [PubMed: 16055774]
- **23. Seo D, Lacadie C, Constable TC, Tuit KL, Sinha R. Disrupted Ventromedial prefrontal function modulates alcohol craving and is predictive of subsequent relapse risk. *JAMA Psychiatry*. May 1.2013 2013, epub online). This is the first study to demonstrate neural correlates of stress-induced and cue-induced alcohol craving and association with future relapse and alcohol use. It identifies the specific pathophysiology of chronic alcohol related adaptations that may contribute to high levels of drug craving which also predict relapse and future alcohol use.
24. Merriam-Webster's Collegiate Dictionary. Eleventh Edition. Merriam-Webster, Inc.; 2004.
25. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. *The American journal of psychiatry*. 2005; 162:1403–1413. [PubMed: 16055761]
26. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, O'Dell LE, Parsons LH, Sanna PP. Neurobiological mechanisms in the transition from drug use to drug dependence. *Neuroscience and Biobehavioral Reviews*. 2004; 27:739–749.
27. Aston-Jones G, Gold JJ. How we say no: norepinephrine, inferior frontal gyrus, and response inhibition. *Biological psychiatry*. 2009; 65:548–549. [PubMed: 19281881]
28. Foltin RW, Haney M. Conditioned effects of environmental stimuli paired with smoked cocaine in humans. *Psychopharmacology*. 2000; 149:24–33. [PubMed: 10789879]
29. Bergquist KL, Fox HC, Sinha R. Self-reports of interoceptive responses during stress and drug cue-related experiences in cocaine- and alcohol-dependent individuals. *Experimental and clinical psychopharmacology*. 2010; 18:229–237. [PubMed: 20545387]
30. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. *Archives of General Psychiatry*. 2006; 63:324–331. [PubMed: 16520439]
31. Sinha R, Shaham Y, Heilig M. Translational and reverse translational research on the role of stress in drug craving and relapse. *Psychopharmacology (Berl)*. 2011
32. Shiffman S, Waters AJ. Negative affect and smoking lapses: a prospective analysis. *Journal of consulting and clinical psychology*. 2004; 72:192–201. [PubMed: 15065954]
33. Hutcherson DM, Everitt BJ, Robbins TW, Dickinson A. The role of withdrawal in heroin addiction: enhances reward or promotes avoidance. *Nature Neuroscience*. 2001; 4(9):943–947.
34. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. *Nature neuroscience*. 2005; 8:1481–1489.
- *35. Schwabe L, Wolf OT. Stress-induced modulation of instrumental behavior: from goal-directed to habitual control of action. *Behav Brain Res*. Jun 1; 2011 219(2):321–8. [PubMed: 21219935]
This is an excellent review of work by these authors and others on stress effects on instrumental behaviors and how stress shifts goal-directed behaviors to habitual action.
36. Richardson HN, Lee SY, O'Dell LE, Koob GF, Rivier CL. Alcohol self-administration acutely stimulates the hypothalamic-pituitary-adrenal axis, but alcohol dependence leads to a dampened neuroendocrine state. *Eur J Neurosci*. 2008; 28:1641–1653. [PubMed: 18979677]
37. Grant S, London ED, Newlin DB, Villemagne VL, Liu X, Contoreggi C, Phillips RL, Kimes AS, Margolin A. Activation of memory circuits during cue-elicited cocaine craving. *Proceedings of the National Academy of Sciences of the United States of America*. 1996; 93:12040–12045. [PubMed: 8876259]

38. Kilts CD, Gross RE, Ely TD, Drexler KP. The neural correlates of cue-induced craving in cocaine-dependent women. *The American journal of psychiatry*. 2004; 161:233–241. [PubMed: 14754771]
39. Li CS, Kosten TR, Sinha R. Sex differences in brain activation during stress imagery in abstinent cocaine users: a functional magnetic resonance imaging study. *Biological psychiatry*. 2005; 57:487–494. [PubMed: 15737663]
40. Sinha R, Li CS. Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications. *Drug and alcohol review*. 2007; 26:25–31. [PubMed: 17364833]
- *41. Potenza MN, Hong KI, Lacadie CM, Fulbright RK, Tuit KL, Sinha R. Neural correlates of stress-induced and cue-induced drug craving: influences of sex and cocaine dependence. *The American Journal of Psychiatry*. 2012; 169:406–414. This is the first study comparing cocaine dependent and healthy social drinking men and women on stress, drug cue and neutral relaxing cues to assess neural correlates of cocaine craving.
42. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, Jayne M, Ma Y, Wong C. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2006; 26:6583–6588. [PubMed: 16775146]
43. Wong DF, Kuwabara H, Schretlen DJ, Bonson KR, Zhou Y, Nandi A, Brasic JR, Kimes AS, Maris MA, Kumar A, et al. Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2006; 31:2716–2727. [PubMed: 16971900]
44. Grusser SM, Wrase J, Klein S, Hermann D, Smolka MN, Ruf M, Weber-Fahr W, Flor H, Mann K, Braus DF, et al. Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. *Psychopharmacology*. 2004; 175:296–302. [PubMed: 15127179]
45. Wrase J, Grusser SM, Klein S, Diener C, Hermann D, Flor H, Mann K, Braus DF, Heinz A. Development of alcohol-associated cues and cue-induced brain activation in alcoholics. *European psychiatry : the journal of the Association of European Psychiatrists*. 2002; 17:287–291. [PubMed: 12381499]
46. Hester R, Garavan H. Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2004; 24:11017–11022. [PubMed: 15590917]
47. Kaufman JN, Ross TJ, Stein EA, Garavan H. Cingulate hypoactivity in cocaine users during a GONOGO task as revealed by event-related functional magnetic resonance imaging. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2003; 23:7839–7843. [PubMed: 12944513]
48. Noel X, Van der Linden M, d'Acremont M, Bechara A, Dan B, Hanak C, Verbanck P. Alcohol cues increase cognitive impulsivity in individuals with alcoholism. *Psychopharmacology*. 2007; 192:291–298. [PubMed: 17279375]
49. Ersche KD, Fletcher PC, Lewis SJ, Clark L, Stocks-Gee G, London M, Deakin JB, Robbins TW, Sahakian BJ. Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. *Psychopharmacology*. 2005; 180:612–623. [PubMed: 16163533]
50. Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ. Profile of executive and memory function associated with amphetamine and opiate dependence. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2006; 31:1036–1047. [PubMed: 16160707]
51. Ersche KD, Roiser JP, Robbins TW, Sahakian BJ. Chronic cocaine but not chronic amphetamine use is associated with perseverative responding in humans. *Psychopharmacology*. 2008; 197:421–431. [PubMed: 18214445]
52. Paulus MP, Tapert SF, Schuckit MA. Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. *Archives of general psychiatry*. 2005; 62:761–768. [PubMed: 15997017]
53. Li C-SR, Huang C, Yan P, Bhagawar Z, Milivojevic V, Sinha R. Neural correlates of impulse control during stop signal inhibition in cocaine dependent men. *Neuropsychopharmacology*. Jul; 2008 33(8):1798–806. [PubMed: 17895916]

- **54. Schwabe L, Tegenthoff M, Hoffken O, Wolf OT. Simultaneous glucocorticoid and noradrenergic activity disrupts the neural basis of goal-directed action in the human brain. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012; 32:10146–10155. [PubMed: 22836250] This is a mechanistic pharmacological manipulation to demonstrate the neural basis of stress disruption of goal-directed action towards habitual action and identifies the medial PFC as a key area responsible for such disruption.
55. Sinha R. Chronic stress, drug use, and vulnerability to addiction. *Annals of the New York Academy of Sciences*. 2008; 1141:105–130. [PubMed: 18991954]

Highlights

- Inclusion of drug craving as a symptom in DSM-V for substance use disorders.
- A craving continuum from normal healthy desire to compulsive seeking is proposed.
- The neurobiology of the shift from desire to compulsive seeking is presented.
- Habitual behaviors may depend on sensitization of brain stress pathways.




FIGURE 1.

A schematic diagram representing drug craving on a dimensional continuum with increasing levels of drug exposure and history is presented. Drug-related neuroadaptations in cortico-striatal limbic networks and neurochemical adaptations that may be examined for their contribution to the drug craving state are highlighted. VTA=ventral tegmental area; HP=hippocampus; CRF=corticotrophin releasing factor; VS=ventral striatum; DA=dopamine; PFC=prefrontal cortex; GABA= Gamma-aminobutyric acid ; Ecb=endocannabinoids.